News | Heart Valve Technology | May 17, 2016

NeoChord Receives FDA Approval to Begin Clinical Trial of DS1000 System

Pivotal study will enroll up to 450 patients in a randomized trial of Artificial Chordae Delivery System for treatment of degenerative mitral valve regurgitation

NeoChord, DS1000 System, FDA approval, U.S. pivotal trial

May 17, 2016 — NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a prospective, multicenter, randomized clinical trial for its Artificial Chordae Delivery System, DS1000.

The pivotal trial will be conducted at 20 U.S. mitral repair centers, according to Lori Adels, Ph.D., vice president of clinical, regulatory and quality at NeoChord. Adels said it is the first U.S. clinical study of a transapical, beating heart procedure for replacement of ruptured or elongated chordae in patients with degenerative mitral valve regurgitation.

Trial protocol was developed in consultation with the FDA and principal investigators David H. Adams, M.D, professor and chairman, Department of Cardiovascular Surgery, Icahn School of Medicine at Mt. Sinia, New York; and Michael A. Borger, M.D., Ph.D., professor and director, Cardiovascular Institute, New York Presbyterian/Columbia University Medical Center, New York. The trial is designed to establish the safety and efficacy of the DS1000 System as an alternative to standard surgical mitral valve repair.

NeoChord received CE Marking approval for the DS1000 System in December 2012 and began marketing the product in Q1 2013. The company plans to expand the commercial availability of the DS1000 System to additional European markets throughout 2016 and 2017.

For more information: www.neochord.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init